BIOELECTRIC MEDICINE • OCULAR SURFACE REPAIR

Programmable bioelectric therapy for corneal repair

Galvanis is developing OcuRegen™, a topical bioelectric therapy designed to restore endogenous wound-field signaling in impaired corneal healing.

Lead indication: persistent corneal epithelial defects (PCED).

Explore OcuRegen™

Science & Mechanism

MECHANISM-CONFIRMED

Quantifiable PD biomarker gates lead selection.

FAST, OBJECTIVE ENDPOINTS

PCED supports fast trials with clear endpoints.

LOCAL DELIVERY

Designed for minimal systemic exposure.

Persistent corneal epithelial defects are vision-threatening lesions that fail to close under standard supportive care. When closure stalls, patients can escalate through bandage lenses, serum-based therapies, amniotic membrane, and other interventions while risk compounds. Galvanis is targeting this setting first because the endpoint is objective, the treatment is local, and the path to translational signal is unusually efficient.

100,000 cases/year; a refractory subset escalates to procedures.
When closure fails, cases step through bandage lenses and autologous serum/PRP, then advanced interventions.
Medicare charges ~$95.6M (2020) on sutureless amniotic membrane grafts.

Non-healing corneal defects threaten vision and drive procedural escalation

No topical therapy is approved specifically for persistent corneal epithelial defects in the United States.

Why Galvanis wins

Corneal repair is not only biochemical. It is bioelectric.

The corneal epithelium maintains a transepithelial potential. When the tissue is wounded, endogenous electric fields form around the defect and help guide directional epithelial migration. Human donor corneas show these wound currents can be modulated pharmacologically. Galvanis is translating that control layer into a topical therapeutic program and advancing candidates only when they clear predefined pharmacodynamic and functional gates.

GO DEEPER ON THE SCIENCE

Pharmacodynamic-gated development with fast go/no-go decisions

We de-risk early by using a quantifiable biomarker (TEP restoration) to screen candidates quickly and avoid late-stage failures associated with variable or ‘black box’ modalities.

Investor snapshot

Key diligence items; full materials available upon request.

RAISE

Galvanis is raising a $900K to run a 24-week, milestone-gated program designed to answer one question with speed and precision: can a topical bioelectric modulator produce a measurable pharmacodynamic signal and an in vivo closure signal in corneal repair?

MILESTONES